Radius nabs $43M round for PhIII bone-building drug

Radius Health joined the lineup of biotechs announcing big new venture rounds today. The Cambridge, MA-based developer, which is focused on new therapies for osteoporosis, says that F2 Biosciences III stepped up to lead the latest round of $43 million. The money will be spent on Radius's lead asset, BA058, a bone-building compound in late-stage development. The injectable BA058-SC is currently in a Phase III trial while BA058-TD is in a Phase II trial designed to study the "efficacy of delivering BA058 via a transdermal patch." Biotech Growth N.V., MPM Capital, Brookside Capital, MPM Bio IV NVS Strategic Fund and BB Biotech Ventures all joined the round, demonstrating the enthusiasm in venture circles for late-stage products. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.